摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-异丙基-2,5-二甲基咪唑 | 49739-24-4

中文名称
1-异丙基-2,5-二甲基咪唑
中文别名
——
英文名称
1-isopropyl-2,5-dimethyl-1H-imidazole
英文别名
1-Isopropyl-2,5-dimethylimidazole;2,5-dimethyl-1-propan-2-ylimidazole
1-异丙基-2,5-二甲基咪唑化学式
CAS
49739-24-4
化学式
C8H14N2
mdl
MFCD09033046
分子量
138.213
InChiKey
RZIAPUVRYIEXHV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    235.2±9.0 °C(Predicted)
  • 密度:
    0.95±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.625
  • 拓扑面积:
    17.8
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • [EN] INHIBITORS OF DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B<br/>[FR] INHIBITEURS DE LA KINASE 1B RÉGULÉE PAR PHOSPHORYLATION DE TYROSINE À DOUBLE SPÉCIFICITÉ
    申请人:TOLREMO THERAPEUTICS AG
    公开号:WO2021064141A1
    公开(公告)日:2021-04-08
    The present invention relates to compounds of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof (I), in particular for use in the treatment, amelioration or prevention of cancer, Alzheimer, Parkinson, Down syndrome, Metabolic syndrome, Diabetes and/or osteoarthritis.
    本发明涉及式(I)的化合物,可选地以药学上可接受的盐、溶剂化合物、共晶、互变异构体、外消旋体、对映体或二对映体或其混合物的形式存在,特别用于治疗、改善或预防癌症、阿尔茨海默病、帕森病、唐氏综合症、代谢综合征、糖尿病和/或骨关节炎。
  • 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:US20150246923A1
    公开(公告)日:2015-09-03
    The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a , A, B 1 , B 2 , G, X 1 , Y 1 , Y 2 , and Y 3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.
    本公开提供了代表为式I的替代的9H-嘧啶并[4,5-b]吲哚5H-吡啶并[4,3-b]吲哚及相关类似物的药用可接受的盐、合物和溶剂合物,其中R1a、A、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用式I的化合物来治疗对BET结构域抑制敏感的状况或疾病。本公开的化合物特别适用于治疗癌症。
  • BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
    申请人:Coferon, Inc.
    公开号:US20140243286A1
    公开(公告)日:2014-08-28
    Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
    本文介绍了一种单体,当在介质中与一个、两个、三个或更多其他单体接触时,能够形成生物上有用的多聚体。在其中一方面,这种单体可以在介质中(例如在体内)与另一个单体结合形成多聚体(例如二聚体)。考虑到的单体可能包括配体基团、连接元素和连接配体基团和连接元素的连接元素。在介质中,这些考虑到的单体可以通过每个连接元素连接在一起,因此可以同时调节一个或多个生物分子,例如调节蛋白质或不同蛋白质上的两个或更多结合结构域。
  • BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME
    申请人:Coferon, Inc.
    公开号:US20140243321A1
    公开(公告)日:2014-08-28
    Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
    本文描述了一种单体,当与一个、两个、三个或更多其他单体在介质中接触时,能够形成生物上有用的多聚体。在一个方面,这样的单体可以在介质中(例如在体内)与另一个单体结合形成多聚体(例如二聚体)。考虑到的单体可能包括配体基团、连接元素和连接配体基团和连接元素的连接器元素。在介质中,这些考虑到的单体可以通过每个连接元素连接在一起,因此可以同时调节一个或多个生物分子,例如调节蛋白质或不同蛋白质上的两个或更多结合域。
  • BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME
    申请人:Coferon, Inc.
    公开号:US20140243322A1
    公开(公告)日:2014-08-28
    Described herein are compounds capable of modulating one or more biomolecules substantially simultaneously, e.g., modulating two or more binding domains (e.g., bromodomains) on a protein or on different proteins.
    本文描述了一些化合物,能够在实质上同时调节一个或多个生物分子,例如,在蛋白质上或不同蛋白质上调节两个或更多结合域(例如结构域)。
查看更多